HC Wainwright Issues Optimistic Outlook for ALNY Earnings

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – HC Wainwright boosted their Q3 2025 earnings per share (EPS) estimates for Alnylam Pharmaceuticals in a report issued on Wednesday, April 2nd. HC Wainwright analyst P. Trucchio now expects that the biopharmaceutical company will post earnings per share of ($0.45) for the quarter, up from their prior estimate of ($0.46). HC Wainwright has a “Buy” rating and a $500.00 price target on the stock. The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is ($1.70) per share. HC Wainwright also issued estimates for Alnylam Pharmaceuticals’ Q4 2025 earnings at $1.38 EPS, FY2025 earnings at ($1.32) EPS and FY2026 earnings at $12.37 EPS.

A number of other analysts also recently issued reports on ALNY. Chardan Capital restated a “buy” rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. Scotiabank raised their target price on Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the stock a “sector outperform” rating in a research note on Monday, March 31st. Sanford C. Bernstein decreased their price target on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. Bank of America raised their price objective on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a “buy” rating in a research report on Friday, March 21st. Finally, Stifel Nicolaus upped their target price on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a “buy” rating in a research report on Monday, March 31st. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $316.25.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock opened at $232.95 on Monday. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The company has a market capitalization of $30.30 billion, a PE ratio of -107.35 and a beta of 0.30. The firm’s 50-day moving average is $258.16 and its two-hundred day moving average is $259.83. Alnylam Pharmaceuticals has a 12 month low of $141.98 and a 12 month high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03).

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. Larson Financial Group LLC increased its stake in Alnylam Pharmaceuticals by 187.2% in the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 73 shares during the last quarter. Park Square Financial Group LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $28,000. R Squared Ltd purchased a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $33,000. OFI Invest Asset Management acquired a new stake in Alnylam Pharmaceuticals during the 4th quarter worth $35,000. Finally, Colonial Trust Co SC purchased a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at $35,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Insider Transactions at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 1,213 shares of the business’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $309,521.21. Following the completion of the transaction, the chief executive officer now owns 81,526 shares in the company, valued at approximately $20,802,989.42. The trade was a 1.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CMO Pushkal Garg sold 1,548 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $251.67, for a total value of $389,585.16. Following the completion of the sale, the chief marketing officer now owns 11,989 shares in the company, valued at approximately $3,017,271.63. This represents a 11.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 71,234 shares of company stock valued at $19,958,097. 1.50% of the stock is currently owned by corporate insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.